Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00002226 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sarcoma, Kaposi HIV Infections | Drug: SU5416 | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 30 participants |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
You may be eligible for this study if you:
- Are at least 18 years old.
- Are HIV-positive.
- Have KS with at least 5 skin lesions.
- Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.
- Agree to use effective methods of birth control during the study.
Exclusion Criteria
You will not be eligible for this study if you:
- Have had surgery within 4 weeks of study entry.
- Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.
- Have pulmonary KS (KS in your lungs).
- Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.
- Are allergic to Cremophor.
- Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).
- Are pregnant.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002226
United States, California | |
Norris Cancer Ctr / USC | |
Los Angeles, California, United States, 90033 | |
UCLA Care Ctr / Ctr for Hlth Sciences | |
Los Angeles, California, United States, 900951793 | |
Saint Francis Mem Hosp / HIV Care Unit | |
San Francisco, California, United States, 94109 | |
United States, New York | |
New York Univ Med Ctr | |
New York, New York, United States, 10016 |
Publications:
ClinicalTrials.gov Identifier: | NCT00002226 History of Changes |
Other Study ID Numbers: |
294A 5416.003 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | June 2000 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
Skin Neoplasms Sarcoma, Kaposi Antineoplastic Agents |
Additional relevant MeSH terms:
HIV Infections Sarcoma Sarcoma, Kaposi Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms |
Herpesviridae Infections DNA Virus Infections Neoplasms, Vascular Tissue Semaxinib Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |